Short Review on Biomarkers for the Diagnosis of Gestational Diabetes

Abstract

About 14% of births, or 135,000 women annually, in the United States are affected by gestational diabetes mellitus (GDM), also known as “impaired glucose tolerance”, which was initially identified during pregnancy. GDM is a parental risk factor for developing type 2 diabetes. GDM raises the likelihood of developing type 2 diabetes (T2DM) and a number of other disorders, as well as unfavorable maternal and fetal outcomes. The improvement of both maternal and fetal health will be made possible by early risk assessment to stop the progression of GDM and by advancements in biomarker testing for the detection of GDM. The value of spectroscopy is that it enables molecular information without the need for specific stains and dyes, which expedites and streamlines the required ex vivo and in vivo testing for medical treatments.